Please ensure Javascript is enabled for purposes of website accessibility
Alex Carchidi

Alex Carchidi

TMFacarchidi

Alex began writing for the Fool in early 2020 and follows companies in the healthcare sector. Formerly a researcher in the biotech industry, he leverages his science background in his work as a writer and entrepreneur. His interests include exploring his hometown of Boston, traveling in Latin America, and value investing.

Recent articles

standing pair of investors consider tablet and computer

Could Cybin Be a Millionaire-Maker Stock?

The "new" mental health therapies this Canadian biotech is developing have an unusual advantage -- there's plenty of existing research showing that they work.


cannabis farmer holds tablet while in field of cannabis

3 Top Pot Stocks to Watch in June

They're firing on all cylinders, and are picking up steam as we enter the summer months.


investor considers writing on glass wall while another sits in the background

Could Mind Medicine Be a Millionaire-Maker Stock?

Yes, but with the chance of great reward comes substantial risk.


investors considers papers on a table while holding a tablet

How to Invest in Meme Stocks Like Sundial Growers and AMC This Summer

Be selective, and have an exit strategy.


two investors consider a stock with laptop

Want to Keep Your Money? Avoid Cannabis Stocks With These 3 Traits

Inefficiency and poor positioning often go hand in hand.

man works at laptop with papers

3 Biotech ETFs That Could Double Your Money by 2025 With Zero Effort

In a sector where picking individual stocks is a high-risk, high-reward strategy, the diversification of exchange-traded funds can be highly appealing.


two workers in a greenhouse

Add This Undervalued Cannabis Stock to Your Watchlist Right Now

It probably won't be a bargain forever.


three investors meet with paperwork

Will Sundial Growers' Banking Play Make Investors Rich?

If the pivot is successful, absolutely.


investor considers papers at a cafe

How to Buy Biotech Stocks This Summer

It pays to know what could cause them to move and when.


frustrated investor at computers

Why Shares of Novavax Crashed 37.7% in May

Delays frustrated investors.

scientist in lab expresses exhaustion

Why Shares of Vaxart Plummeted 38.6% in May

This isn't the first time its coronavirus vaccine pill has disappointed investors.


doctor showing brain image to two people

This Biotech Stock Is Up 884% In 2021, But It Could Go Even Higher

With updates from clinical trials expected as soon as this month, anything is possible.


investor looks at book with consternation

Why Shares of MindMed Dropped 13% in May

Froth from its uplisting is having an impact.


four chemists examine data in lab

This New Product Is Central to mRNA Vaccines -- But Should You Buy the Stock?

The income could be a slow burn.


researcher with microscope and two genetic data readouts

Will Illumina Be a Trillion-Dollar Stock by 2035?

It'll cover a lot of ground in the next 14 years.

doctor does a telehealth visit with laptop and phone

3 Reasons to Buy Teladoc, and 1 Reason To Sell

Things are different for the business in 2021 as lock-downs disappear and people venture out.


cannabis farmer inspects plant in field

Could OrganiGram Double Again by 2022?

It's more likely than it sounds.


investor works late at night

Is STAAR Surgical a Warren Buffett Stock?

He'd appreciate its margins and its moat.


investor sitting with laptop and dog

This Biotech Penny Stock Is Better Than Dogecoin

You might want to avoid buying it, though.


couple is troubled by finances

Afraid of the Dogecoin Bubble? Avoid These 2 Investing Mistakes

It helps to be realistic about valuation and timing.